So let me just start with the longer-term and work our way back to the short-term. You know what this product really does is, it is intended to assure that when people, particularly those who are in employer-based health plans, but the product also works for plan sponsored individual plans, if there's demand there. But when folks are going to pay their out-of-pocket expenses, their ability to get care at that point really shouldn't be limited by their credit limit or credit score. It is just not the right answer in our view. And the product gives employers and health plans a very cost-effective way to get to avoid that. And so my view is that this will have relatively broad applicability out there both to people who might be using HSAs or the other health accounts, but also to the broader population, including those that don't. And remember that even at market maturity, right, we don't expect that everyone is going to have an HSA or the like. And so we think that over time, this could be rather significant. And the goal -- the mid-term goal we've said kind of internally is -- and this is -- and in my view, part of sort of establishing this as part of benefits package that standard is we would like to see within the next three years, four years here, one of those in group coverage have access to that. That seems like a highly achievable goal. Now -- so -- that seems fine for the relatively near-term and then go from there. So it's establishing something new that in a way is back to the past. When folks had HMO plans with little choice and whatnot, they typically -- these costs were being covered in the same way. They were just in premiums. And so it is sort of in a way going back to that from a cash flow management perspective. The short-term, with regard to, obviously no impact in fiscal '25, we do anticipate a modest impact in fiscal '26 as observers of our release can see on this topic. There are clients of ours who have been testing out this product, including large ones and with, in my mind, really good response, both in terms of the quantity and also, I think more importantly, the quality of how it's being used. And so we do think there will be a modest impact in 2026, a more significant impact as the thing catches on in '27 and '28. So we'll certainly reflect that as we get to '26 guidance. But this is a good product. I mean we've been thinking about how to do this, Steve, how long does it go back that we've been mucking around with products to solve this problem. 10 years, maybe longer?